2022年全球肝癌与胆囊癌发病死亡及2050年预测分析

摘要/Abstract

摘要： 目的：分析2022年全球肝癌和胆囊癌流行病学现状,预测至2050年全球肝癌和胆囊癌发病死亡负担。
方法：基于国际癌症研究机构（International Agency for Research on Cancer,IARC）2024年2月发布的GLOBOCAN 2022数据库,分析2022年并预测至2050年全球肝癌和胆囊癌疾病负担。年龄标准化发病率和死亡率使用Segi’s世界标准人口结构数据计算。新发及死亡病例预测基于《世界人口展望》预计人口估算。
结果：2022年全球肝癌新发病例866 136例,死亡病例758 725例,标准化发病率和死亡率分别为8.6/10万和7.4/10万。2022年全球胆囊癌新发病例122 491例,死亡病例89 055例,标准化发病率和死亡率分别为1.2/10万和0.83/10万。不同年龄组男性肝癌发病率、死亡率均高于女性;女性胆囊癌发病率、死亡率均高于男性。在全球185个国家中,蒙古国肝癌标准化发病率和死亡率最高,玻利维亚胆囊癌标准化发病率和死亡率最高。2050年肝癌预测新发病例1 564 034例、死亡病例1 420 926例,分别较2022年上涨约80.6%、87.3%;胆囊癌预测新发病例235 096例、死亡病例176 725例,分别较2022年上涨约91.9%、98.4%。2050年非洲肝癌和胆囊癌新发和死亡病例涨幅最大。
结论：各国肝癌和胆囊癌疾病负担存在差异,疾病负担较重及快速增长的地区（如亚洲、非洲等）或国家（如蒙古国、玻利维亚等）应更加积极主动采取癌症防控措施。

关键词: 肝癌, 胆囊癌, 发病率, 死亡率, 预测, 全球

Abstract: Objective: To analyze the global epidemiological profiles of liver and gallbladder cancer in 2022, and project the global burden of cancer incidence and mortality until 2050.
Methods: Based on the GLOBOCAN 2022 database, we analyzed the global burden of liver and gallbladder cancer in 2022 and the projected disease burden in 2050. We calculated age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) by using Segi's world standard population structure data. We estimated the future number of cases and deaths by 2050 based on world population prospects.
Results: In 2022, there were an estimated 866,136 new cases and 758,725 deaths from liver cancer, corresponding to ASIRs and ASMRs of 8.6 per 100,000 and 7.4 per 100,000, respectively. There were an estimated 122,491 new cases and 89,055 deaths from gallbladder cancer, corresponding to ASIRs and ASMRs of 1.2 per 100,000 and 0.83 per 100,000, respectively. Incidence and mortality rates of liver cancer were higher in males than in females across different age groups, and gallbladder cancer displayed higher rates among females compared to males. The country with the highest ASIR and ASMR for liver cancer was Mongolia. For gallbladder cancer, Bolivia reported the highest ASIR and ASMR. By 2050, the annual number of new cases and deaths from liver cancer will increase to 1,564,034 (an 80.6 percent increase from the year 2022) and 1,420,926 (an 87.3 percent increase), respectively. The annual number of new cases and deaths from gallbladder cancer will increase to 235,096 (a 91.9 percent increase from the year 2022) and 176,725 (a 98.4 percent increase), respectively. Africa has the largest increase in both projected new cases and deaths from liver and gallbladder cancer globally in 2050.
Conclusions: Inequities in liver and gallbladder disease burden persist worldwide. Regions such as Asia and Africa, as well as countries such as Mongolia and Bolivia, which face heavy disease burden and rising incidence rates, must prioritize the establishment of cancer control initiatives.

Key words: Liver cancer, Gallbladder cancer, Incidence, Mortality, Projection, World

刘曼琪, 徐梦圆, 单天昊, 赵宏, 曾红梅, 蔡建强. 2022年全球肝癌与胆囊癌发病死亡及2050年预测分析[J]. 肝癌电子杂志, 2024, 11(2): 53-60.

Liu Manqi, Xu Mengyuan, Shan Tianhao, Zhao Hong, Zeng Hongmei, Cai Jianqiang. Global liver and gallbladder cancer incidence and mortality in 2022 and projections to 2050[J]. Electronic Journal of Liver Tumor, 2024, 11(2): 53-60.

参考文献

[1] UGAI T, SASAMOTO N, LEE H Y, et al.Is early-onset cancer an emerging global epidemic? Current evidence and future implications[J]. Nat Rev Clin Oncol, 2022, 19(10): 656-673.
[2] VAN DYKE A L, SHIELS M S, JONES G S, et al. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013[J]. Cancer, 2019, 125(9): 1489-1498.
[3] SIEGEL R L, MILLER K D, WAGLE N S, JEMAL A.Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
[4] MAO W, DENG F, WANG D, et al.Treatment of advanced gallbladder cancer: a SEER-based study[J]. Cancer Med, 2020, 9(1): 141-150.
[5] SIEGEL R L, GIAQUINTO A N, JEMAL A.Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49.
[6] KHANALI J, MALEKPOUR M R, AZANGOU-KHYAVY M, et al.Global, regional, and national quality of care of gallbladder and biliary tract cancer: a systematic analysis for the global burden of disease study 1990-2017[J]. Int J Equity Health, 2021, 20(1): 259.
[7] FODA Z H, ANNAPRAGADA A V, BOYAPATI K, et al.Detecting liver cancer using cell-free DNA fragmentomes[J]. Cancer Discov, 2023, 13(3): 616-631.
[8] BRAY F, GUILLOUX A, SANKILA R, PARKIN D M.Practical implications of imposing a new world standard population[J]. Cancer Causes Control, 2002, 13(2): 175-182.
[9] BRAY F, LAVERSANNE M, SUNG H, et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[10] FLORIO A A, FERLAY J, ZNAOR A, et al.Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012[J]. Cancer, 2020, 126(11): 2666-2678.
[11] 安澜,曾红梅,郑荣寿,等.2015年中国肝癌流行情况分析[J].中华肿瘤杂志,2019,41(10):721-727.
[12] RUMGAY H, FERLAY J, DE MARTEL C, et al.Global, regional and national burden of primary liver cancer by subtype[J]. Eur J Cancer, 2022, 161: 108-118.
[13] LLOVET J M, KELLEY R K, VILLANUEVA A, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6.
[14] ARNOLD M, ABNET C C, NEALE R E, et al. Global burden of 5 major types of gastrointestinal cancer[J]. Gastroenterology, 2020, 159(1): 335-349.e15.
[15] FENG C, LIU J, RAN H, et al.Spatial and temporal analysis of liver cancer mortality in Yunnan province, China, 2015-2019[J]. Front Public Health, 2022, 10: 1010752.
[16] ZHANG C H, CHENG Y, ZHANG S, et al.Changing epidemiology of hepatocellular carcinoma in Asia[J]. Liver Int, 2022, 42(9): 2029-2041.
[17] YUEN M F, CHEN D S, DUSHEIKO G M, et al.Hepatitis B virus infection[J]. Nat Rev Dis Primers, 2018, 4: 18035.
[18] GBD 2019 DISEASES AND INJURIES COLLABORATORS. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019BD 2019 DISEASES AND INJURIES COLLABORATORS. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019[J]. Lancet, 2020, 396(10258): 1204-1222.
[19] BROWN Z J, TSILIMIGRAS D I, RUFF S M, et al.Management of hepatocellular carcinoma: a review[J]. JAMA Surg, 2023, 158(4): 410-420.
[20] SINGAL A G, LAMPERTICO P, NAHON P.Epidemiology and surveillance for hepatocellular carcinoma: new trends[J]. J Hepatol, 2020, 72(2): 250-261.
[21] 单天昊,安澜,徐梦圆,等. 2020年全球肝癌和胆囊癌发病死亡分析[J/CD]. 肝癌电子杂志,2022,9(4):46-51.
[22] TORRENS L, PUIGVEHÍ M, TORRES-MARTÍN M, et al. Hepatocellular carcinoma in mongolia delineates unique molecular traits and a mutational signature associated with environmental agents[J]. Clin Cancer Res, 2022, 28(20): 4509-4520.
[23] ZNAOR A, CHIMED T, LAVERSANNE M, et al.The public health challenge of liver cancer in Mongolia[J]. Lancet Gastroenterol Hepatol, 2018, 3(10): 660-662.
[24] DASHTSEREN B, BUNGERT A, BAT-ULZII P, et al.Endemic prevalence of hepatitis B and C in Mongolia: A nationwide survey amongst Mongolian adults[J]. J Viral Hepat, 2017, 24(9): 759-767.
[25] CAO M, FAN J, LU L, et al.Long term outcome of prevention of liver cancer by hepatitis B vaccine: Results from an RCT with 37 years[J]. Cancer Lett, 2022, 536: 215652.
[26] YANG J D, HAINAUT P, GORES G J, et al.A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.
[27] 黄瑜,刘玉琴,丁高恒,等. 2009—2015年甘肃省肿瘤登记地区胆囊癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志,2021,35(3):193-199.
[28] MOORE S P, FORMAN D, PIÑEROS M, et al. Cancer in indigenous people in Latin America and the Caribbean: a review[J]. Cancer Med, 2014, 3(1): 70-80.
[29] NEMUNAITIS J M, BROWN-GLABEMAN U, SOARES H, et al.Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico[J]. BMC Cancer, 2018, 18(1): 665.
[30] JACKSON S S, MARKS M A, KATKI H A, et al.Sex disparities in the incidence of 21 cancer types: quantification of the contribution of risk factors[J]. Cancer, 2022, 128(19): 3531-3540.
[31] SUNG H, FERLAY J, SIEGEL R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[32] ROA J C, GARCÍA P, KAPOOR V K, et al. Gallbladder cancer[J]. Nat Rev Dis Primers, 2022, 8(1): 69.
[33] HUNDAL R, SHAFFER E A.Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol, 2014, 6: 99-109.
[34] YUAN B, ZHAO X, WANG X, et al.Patient-derived organoids for personalized gallbladder cancer modelling and drug screening[J]. Clin Transl Med, 2022, 12(1): e678.
[35] NIE C, YANG T, LIU L, HONG F.Trend analysis and risk of gallbladder cancer mortality in China, 2013-2019[J]. Public Health, 2022, 203: 31-35.
[36] TORRE L A, SIEGEL R L, ISLAMI F, et al.Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers[J]. Clin Gastroenterol Hepatol, 2018, 16(3): 427-437.
[37] FEO C F, GINESU G C, FANCELLU A, et al.Current management of incidental gallbladder cancer: a review[J]. Int J Surg, 2022, 98: 106234.
[38] WERNBERG J A, LUCARELLI D D.Gallbladder cancer[J]. Surg Clin North Am, 2014, 94(2): 343-360.
[39] BRANCH OF BILIARY SURGERY, CHINESE SURGICAL SOCIETY; CHINESE COMMITTEE OF BILIARY SURGEONS. Guideline for the diagnosis and treatment of gallbladder carcinoma (2019 edition)[J]. Zhonghua Wai Ke Za Zhi, 2020, 58(4): 243-251.
[40] ALMANZA-AGUILERA E, CANO A, GIL-LESPINARD M, et al.Mediterranean diet and olive oil, microbiota, and obesity-related cancers. From mechanisms to prevention[J]. Semin Cancer Biol, 2023, 95: 103-119.
[41] AHMED I, HUDSON J, INNES K, et al.Effectiveness of conservative management versus laparoscopic cholecystectomy in the prevention of recurrent symptoms and complications in adults with uncomplicated symptomatic gallstone disease (C-GALL trial): pragmatic, multicentre randomised controlled trial[J]. BMJ, 2023, 383: e075383.
[42] RUMGAY H, ARNOLD M, FERLAY J, et al.Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77(6): 1598-1606.
[43] LI C, HE W Q.Global prediction of primary liver cancer incidences and mortality in 2040[J]. J Hepatol, 2023, 78(4): e144-e146.
[44] NAN Y, XU X, DONG S, et al.Consensus on the tertiary prevention of primary liver cancer[J]. Hepatol Int, 2023, 17(5): 1057-1071.
[45] HUANG J, LUCERO-PRISNO D E, 3RD, ZHANG L, et al. Updated epidemiology of gastrointestinal cancers in East Asia[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(5): 271-287.